Hillstream BioPharma Inc

NASDAQ:HILSUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Hillstream BioPharma, Inc. (HBI) is a pre-clinical biotechnology company. The Company is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The drug HSB-1216 was found to reduce tumor in burden treatment resistant cancers, including triple negative breast cancer and epithelial carcinomas. The Company uses Quatramer, a tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment (TME). Its Trident Artificial Intelligence, an artificial intelligence precision medicine platform used to identify biomarkers in clinical programs to target specific patient segments. The Company’s pipeline includes HSB-1216, HSB-888, HSB-510 and HSB-114. HSB-1216 pipeline is a novel inducer of iron-mediated cell death.

Contact Information

Headquarters

1200 Route 22 East, Suite 2000BRIDGEWATER, NJ, United States 08807

Phone

908-955-3140

Fax

302-645-1280

Executives

Chairman of the Board, President, Chief Executive Officer

Randy Milby

Chief Financial Officer

Thomas Hess

Independent Director

Sireesh Appajosyula

Independent Director

Lynne Bui

Independent Director

Leonard Mazur